Ms Falberg is currently CFO and COO of Arca biopharma and has over 20 years of experience as a financial executive and corporate director.
Ms Falberg’s career includes seven years at Amgen, where she served as senior vice president and CFO, as well as vice-president, controller and chief accounting officer and treasurer.
Ms Falberg currently serves as chair of the audit committees for Halozyme and ESS Technology. Ms Falberg has received a BA and an MBA from the University of California, Los Angeles.
Boyd Clarke, chairman of the board at QLT, said: “Kate brings a wealth of experience and we are pleased to welcome her to our board. Kate brings a robust financial and strategic skill set and strong industry background in biotechnology. We believe that QLT will greatly benefit from Kate’s operational and financial experience.”